▲ Peaking
Business
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has unveiled clinical trial data for a KRAS-targeting drug combination aimed at treating metastatic pancreatic cancer.
2 trends tracked about this subject — the full history, oldest to newest below.
Revolution Medicines has unveiled clinical trial data for a KRAS-targeting drug combination aimed at treating metastatic pancreatic cancer.
Roche's KRAS lung-cancer drug candidate has outperformed existing therapies in a late-stage clinical trial.